ReviewDrug design, development and therapy2026
Peripartum Esketamine: A Narrative Review of Analgesia, Postpartum Depressive Symptoms, Sleep-Related Outcomes, and Safety.
Review in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pain, depressive symptoms, and sleep disruption frequently overlap during the peripartum period, although their relationships are associative rather than established as causal. Esketamine, an N-methyl-D-aspartate receptor antagonist, has attracted interest as a peripartum intervention with potential effects on pain, mood, and sleep. This narrative review evaluates the clinical and mechanistic evidence for peripartum esketamine in analgesia, postpartum depressive symptoms, sleep-related outcomes, and maternal-infant safety, with particular attention to the directness and interpretability of the evidence. Most direct clinical evidence derives from cesarean-delivery studies, many of which are single-center trials. Evidence is most consistent for short-term analgesic benefit, whereas opioid-sparing effects are less consistent across individual studies and evidence syntheses. Several randomized trials suggest that low-dose peri-delivery esketamine may reduce early EPDS-defined screen-positive postpartum depressive symptoms, while evidence based on structured diagnostic outcomes remains limited. Evidence for sleep-related benefit remains preliminary and relies predominantly on subjective measures, with no direct postpartum polysomnographic evidence. Studied low-dose regimens have generally shown acceptable short-term maternal and neonatal tolerability in selected populations, but pregnancy-specific pharmacokinetics, lactation, and long-term offspring neurodevelopment remain insufficiently characterized. Overall, esketamine may represent an individualized adjunct in peripartum care, but current evidence does not support its routine prophylactic use. Future multicenter studies should incorporate diagnostic mood outcomes, objective sleep assessment, standardized treatment protocols, and long-term maternal and infant follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.